| (21) | N° Dépôt : 42864 | | (22) | Date de Dépôt : 25.09.2013 | | (30) | Données de Priorité : 26.09.2012 US 61/705,791 | | (86) | Données relatives à l'entrée en phase nationale selon le PCT : PCT/EP2013/06989225.09.2013 | | (71) | Demandeur(s) : F.HOFFMANN-LA ROCHE AG,, Grenzacherstrasse 124 CH-4070 Basel (CH) | | (72) | Inventeur(s) : BLACKABY, WESLEY ; BURCH, JASON ; HODGES, ALASTAIR, JAMES ; SHARPE, ANDREW ; SUN, MINGHUA ; WANG, XIAOJING | | (74) | Mandataire : SABA & CO | | (54) | Titre : COMPOSES D’ÉTHER CYCLIQUE-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE ET PROCÉDÉS D'UTILISATION | | (57) | Abrégé : Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. |
|
